Institutional equity research analysts covering American Healthcare REIT overwhelmingly maintain a consensus buy rating on the security. Positive sentiment is reinforced by strong normalized funds from operations outperformance, disciplined expense control, and upward revisions to full-year financial guidance. With average 12-month analyst price targets extending higher than current trading levels, the majority of Wall Street watchers categorize the stock as a favorable addition for portfolios seeking healthcare real estate exposure.